Axsome Therapeutics Inc
NASDAQ:AXSM

Watchlist Manager
Axsome Therapeutics Inc Logo
Axsome Therapeutics Inc
NASDAQ:AXSM
Watchlist
Price: 171.49 USD -4.03% Market Closed
Market Cap: 8.6B USD

Axsome Therapeutics Inc
Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Axsome Therapeutics Inc
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Axsome Therapeutics Inc
NASDAQ:AXSM
Common Stock
$10k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Common Stock
$3.1B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Bristol-Myers Squibb Co
NYSE:BMY
Common Stock
$292m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
3%
Pfizer Inc
NYSE:PFE
Common Stock
$481m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Merck & Co Inc
NYSE:MRK
Common Stock
$1.8B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Eli Lilly and Co
NYSE:LLY
Common Stock
$591.4m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
-2%
No Stocks Found

Axsome Therapeutics Inc
Glance View

Axsome Therapeutics Inc. emerged as a dynamic player in the biopharmaceutical arena, driven by a resolute commitment to alleviate the burdensome effects of central nervous system (CNS) disorders. Founded with a vision to fill critical treatment gaps in neurologically influenced conditions, Axsome leverages innovative drug discovery and development to address medical needs that have long been underserved. The company focuses intently on conditions such as depression, migraine, narcolepsy, and Alzheimer's disease-related agitation, channeling resources into a streamlined pipeline that seeks to fast-track the development and commercialization of life-changing therapies. Operating at the intersection of cutting-edge science and patient-centric healthcare, Axsome generates revenue through the successful approval and marketing of its proprietary pharmaceutical products. The company's business model hinges on advancing its clinical candidates through rigorous trials, eventually gaining the necessary regulatory endorsements to bring them to market. By holding the intellectual property rights for these novel drugs, Axsome enjoys the advantages of exclusivity in the marketplace, which allows it to negotiate favorable pricing and reimbursement terms. This strategic approach not only positions Axsome as a potentially transformative force within the pharmaceutical industry but also underlines its commitment to producing viable, accessible treatments for those grappling with debilitating CNS disorders.

AXSM Intrinsic Value
141.51 USD
Overvaluation 17%
Intrinsic Value
Price

See Also

What is Axsome Therapeutics Inc's Common Stock?
Common Stock
10k USD

Based on the financial report for Sep 30, 2025, Axsome Therapeutics Inc's Common Stock amounts to 10k USD.

What is Axsome Therapeutics Inc's Common Stock growth rate?
Common Stock CAGR 1Y
0%

Over the last year, the Common Stock growth was 0%.

Back to Top